Addex reports anti-tussive activity of GABAB positive allosteric modulator
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 06 2025
0mins
Addex Therapeutics' GABAB PAM Drug Candidate: Addex Therapeutics has demonstrated strong anti-tussive effects of its GABAB receptor positive allosteric modulator in preclinical models, showing superior efficacy compared to traditional cough medications like nalbuphine and codeine.
Presentation at American Cough Conference: The findings will be presented by Mikhail Kalinichev at the 10th American Cough Conference on June 7, highlighting the drug's ability to reduce cough frequency and improve tolerability without developing tolerance.
Analyst Views on ADXN
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
